SAN DIEGO--(BUSINESS WIRE)--BioAuxilium Research Inc., a Canadian biotech specialized in the development of custom TR-FRET assay kits, announced today at the 2017 BIO International Convention the successful development of its 100th custom TR-FRET immunoassay kit. These easy-to-use, fully validated assay kits provide researchers with homogeneous, robust and highly sensitive assays that simplify laboratory workflow and accelerate drug discovery and life science research.
BioAuxilium’s custom immunoassay kits use the robust TR-FRET technology, which combines the sensitivity and low background of time-resolved fluorescence with the homogeneous nature of FRET. This technology does not require plate coating, washing or separation steps, thereby allowing considerable time-savings compared with standard ELISA.
“BioAuxilium is responding to an increasing demand for custom assay kit development using the TR-FRET technology. We are very pleased to have quickly reached this important milestone. These custom products were developed and validated within a 15-month timeframe period, which highlights our experience and expertise in assay reagent and kit development,” said Jaime Padros, Ph.D., President, BioAuxilium. “Our custom assay kit development service brings together our industry-validated new product development process, in depth knowledge of TR-FRET and expert scientific insight that allow our partners to mitigate risks, manage costs and meet aggressive timelines.”
About BioAuxilium Research Inc.
BioAuxilium is a private Canadian biotechnology company founded by expert industry scientists and focused on the design, development and manufacturing of custom, ready-to-use TR-FRET assay kits to support the biopharmaceutical industry and related life science research communities. BioAuxilium also provides customized services in biochemical and cell-based assay development on a contract basis using a range of assay technologies.